



# Questions to ask your doctor

## about ovarian cancer maintenance treatment with ZEJULA (niraparib)

1. Is ZEJULA (niraparib) the right treatment for me?
2. What is maintenance therapy and why is it different to chemotherapy?
3. When would I start taking a maintenance therapy like ZEJULA (niraparib)?
4. How does ZEJULA (niraparib) work?
5. What potential side effects do I need to be aware of whilst taking ZEJULA (niraparib)?
6. Will I need ongoing monitoring and blood tests whilst on ZEJULA (niraparib)?
7. What else should I know before I start taking ZEJULA (niraparib)?
8. Do I need to take ZEJULA (niraparib) in hospital, like chemotherapy?
9. How long will I need to take ZEJULA (niraparib) for?
10. Is ZEJULA (niraparib) fully funded?



**NOW FULLY FUNDED\***<sup>1</sup>  
\*Special Authority criteria applies

### Zejula Safety Information<sup>2</sup>:

- Hypersensitivity to the active substance or any excipients.
- Breast feeding is contraindicated during administration of Zejula and for 1 month after receiving the last dose.

### References:

1. PHARMAC Community Schedule Online. Available at: <https://schedule.pharmac.govt.nz/ScheduleOnline.php> (Accessed December 2024) 2. GlaxoSmithKline NZ ZEJULA Data Sheet 2024. Available at: <https://www.medsafe.govt.nz/profs/datasheet/z/zejulacap.pdf> (Accessed August 2025)

By clicking the links, you will be re-directed to a website not owned or monitored by GSK, and GSK is not responsible for the content of that website.

**Any information provided on this website should be discussed with your Health Care Professional and does not replace Health Care Professional advice. This site is intended for NZ audience only.**

**ZEJULA** (niraparib: 100mg capsules and tablets) is a **prescription medicine** used in adults for the treatment of cancer of the ovary, the fallopian tubes or the peritoneum. It is used for the treatment of cancer that has responded to first treatment with platinum-based chemotherapy or come back (recurred) after the cancer has responded to previous treatment with standard platinum-based chemotherapy. **ZEJULA is fully funded for the treatment of advanced and recurrent ovarian cancer; Special Authority criteria apply. ZEJULA has risks and benefits and should be initiated and supervised by a doctor experienced in the use of anticancer medicines. Ask your doctor if ZEJULA is right for you. If your symptoms worsen or you have side effects, see your doctor, pharmacist or healthcare professional. Use strictly as directed. Normal doctor charges apply. Additional product information and Consumer Medicine Information (CMI) is available at <https://www.medsafe.govt.nz/Consumers/cmi/z/zejula.pdf>.** Trademarks are owned by or licensed to the GSK group of companies. ©2024 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. **Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS NP21969 PM-NZ-NRP-WCNT-250006 Date of Approval: 09 2025 Date of Expiry: 09 2027**